51
|
Weinblatt M, McInnes I, Kremer J, Miranda P, Vencovský J, Godwood A, Albulescu M, Close D, Burmester G. SAT0146 Earth Explorer 2, A Phase IIB Exploratory Study Evaluating Efficacy and Safety of Mavrilimumab, A Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-Alpha Monoclonal Antibody, and The Tumor Necrosis Factor Antagonist Golimumab in Rheumatoid Arthritis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3453] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
52
|
Emery P, Burmester G, Bykerk V, Combe B, Furst D, Maldonado M, Huizinga T. SAT0153 Abatacept plus Methotrexate Can Effectively and Safely Regain The Target of Remission Following Re-Treatment for Flares after Drug-Free Withdrawal in Patients with Early Rheumatoid Arthritis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.2054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
53
|
Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Bykerk V, Dougados M, Emery P, Haraoui B, Gomez-Reino J, Kvien TK, Nash P, Navarro-Compán V, Scholte-Voshaar M, van Vollenhoven R, van der Heijde D, Stamm TA. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis 2016; 75:16-22. [PMID: 25990290 PMCID: PMC4717391 DOI: 10.1136/annrheumdis-2015-207526] [Citation(s) in RCA: 176] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2015] [Revised: 04/20/2015] [Accepted: 04/30/2015] [Indexed: 12/14/2022]
Abstract
OBJECTIVE A systematic literature review (SLR; 2009-2014) to compare a target-oriented approach with routine management in the treatment of rheumatoid arthritis (RA) to allow an update of the treat-to-target recommendations. METHODS Two SLRs focused on clinical trials employing a treatment approach targeting a specific clinical outcome were performed. In addition to testing clinical, functional and/or structural changes as endpoints, comorbidities, cardiovascular risk, work productivity and education as well as patient self-assessment were investigated. The searches covered MEDLINE, EMBASE, Cochrane databases and Clinicaltrial.gov for the period between 2009 and 2012 and separately for the period of 2012 to May of 2014. RESULTS Of 8442 citations retrieved in the two SLRs, 176 articles underwent full-text review. According to predefined inclusion/exclusion criteria, six articles were included of which five showed superiority of a targeted treatment approach aiming at least at low-disease activity versus routine care; in addition, publications providing supportive evidence were also incorporated that aside from expanding the evidence provided by the above six publications allowed concluding that a target-oriented approach leads to less comorbidities and cardiovascular risk and better work productivity than conventional care. CONCLUSIONS The current study expands the evidence that targeting low-disease activity or remission in the management of RA conveys better outcomes than routine care.
Collapse
|
54
|
Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewé R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Cañete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2015; 75:499-510. [PMID: 26644232 DOI: 10.1136/annrheumdis-2015-208337] [Citation(s) in RCA: 619] [Impact Index Per Article: 68.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2015] [Accepted: 10/30/2015] [Indexed: 12/12/2022]
Abstract
BACKGROUND Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations. METHODS A systematic literature review was performed regarding pharmacological treatment in PsA. Subsequently, recommendations were formulated based on the evidence and the expert opinion of the 34 Task Force members. Levels of evidence and strengths of recommendations were allocated. RESULTS The updated recommendations comprise 5 overarching principles and 10 recommendations, covering pharmacological therapies for PsA from non-steroidal anti-inflammatory drugs (NSAIDs), to conventional synthetic (csDMARD) and biological (bDMARD) disease-modifying antirheumatic drugs, whatever their mode of action, taking articular and extra-articular manifestations of PsA into account, but focusing on musculoskeletal involvement. The overarching principles address the need for shared decision-making and treatment objectives. The recommendations address csDMARDs as an initial therapy after failure of NSAIDs and local therapy for active disease, followed, if necessary, by a bDMARD or a targeted synthetic DMARD (tsDMARD). The first bDMARD would usually be a tumour necrosis factor (TNF) inhibitor. bDMARDs targeting interleukin (IL)12/23 (ustekinumab) or IL-17 pathways (secukinumab) may be used in patients for whom TNF inhibitors are inappropriate and a tsDMARD such as a phosphodiesterase 4-inhibitor (apremilast) if bDMARDs are inappropriate. If the first bDMARD strategy fails, any other bDMARD or tsDMARD may be used. CONCLUSIONS These recommendations provide stakeholders with an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion.
Collapse
|
55
|
Emery P, Burmester G, Bykerk V, Combe B, Furst D, Barre E, Karyekar C, Wong D, Huizinga T. OP0026 Induction of Clinical Remission Followed by Drug-Free Withdrawal with Abatacept Combination and Monotherapy in Early RA: Results from the AVERT Study over 18 Months. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2132] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
56
|
Burmester G, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, Rangaraj M, Roane G, Ludivico C, Mysler E, Bennett M, Rowell L, Bao M. FRI0316 The Efficacy and Safety of Subcutaneous Tocilizumab versus Intravenous Tocilizumab in Combination with Traditional DMARDS in Patients with RA at Week 97 (SUMMACTA). Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1347] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
57
|
Peterfy C, Burmester G, Bykerk V, Combe B, Furst D, Huizinga T, Karyekar C, Wong D, Conaghan P, Emery P. OP0030 Mri Results from the AVERT Study: A Randomized, Active-Controlled TRIAL to Evaluate Induction of Remission and Maintenance of Drug-Free Remission Using Abatacept in Combination with Methotrexate or as Monotherapy in Patients with Early RA: Table 1. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
58
|
Burmester G, Blanco R, Keiserman M, Rigby W, van Vollenhoven R, Dimonaco S, Grzeschik S, Mitchell N. SAT0226 Tocilizumab (TCZ) as Combination Therapy and as Monotherapy VS Methotrexate (MTX) in MTX-Naive Patients with Early Rheumatoid Arthritis: Patient-Reported Outcomes (PROS) from A Randomized, Placebo-Controlled Trial. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2178] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
59
|
Witt M, Grunke M, Proft F, Baeuerle M, Aringer M, Burmester G, Chehab G, Fiehn C, Fischer-Betz R, Fleck M, Freivogel K, Haubitz M, Kötter I, Lovric S, Metzler C, Rubberth-Roth A, Schwarting A, Specker C, Tony HP, Unger L, Wassenberg S, Dörner T, Schulze-Koops H. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). Lupus 2014; 22:1142-9. [PMID: 24057058 DOI: 10.1177/0961203313503912] [Citation(s) in RCA: 63] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
OBJECTIVE The objective of this article is to evaluate the safety and clinical outcome of rituximab treatment in systemic lupus erythematosus (SLE) patients refractory to standard of care therapy in a real-life setting in Germany. METHODS The GRAID registry included patients with different autoimmune diseases who were given off-label treatment with rituximab. Data on safety and clinical response were collected retrospectively. In SLE patients, clinical parameters included tender and swollen joint counts, fatigue, myalgia, general wellbeing, Raynaud's and the SLEDAI index. Laboratory tests included dsDNA antibody titres, complement factors, hematologic parameters and proteinuria. Finally, the investigators rated their patients as non-, partial or complete responders based on clinical grounds. RESULTS Data from 85 SLE patients were collected, 69 female and 16 male, with a mean disease duration of 9.8 years. The mean follow-up period was 9.6 ± 7.4 months, resulting in 66.8 patient years of observation. A complete response was reported in 37 patients (46.8%), partial response in 27 (34.2%), no response in 15 (19.0%). On average, major clinical as well as laboratory efficacy parameters improved substantially, with the SLEDAI decreasing significantly from 12.2 to 3.3 points. Concerning safety, one infusion reaction leading to discontinuation of treatment occurred. Infections were reported with a rate of 19.5 (including six severe infections) per 100 patient years. CONCLUSION With the restrictions of a retrospective data collection, the results of this study confirm data of other registries, which suggest a favourable benefit-risk ratio of rituximab in patients with treatment-refractory SLE.
Collapse
|
60
|
Burmester G, Kivitz A, van Vollenhoven RF, Florentinus S, Karunaratne PM, Kupper H, Dougados M, Fleischmann R. 91. Methotrexate dose has Minimal Effect on Methotrexate-Related Toxicity in Patients with Early Rheumatoid Arthritis Treated in Combination with Adalimumab: Results of Concerto Trial. Rheumatology (Oxford) 2014. [DOI: 10.1093/rheumatology/keu101.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
61
|
Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JWJ, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JMW, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PLCM, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73:492-509. [PMID: 24161836 PMCID: PMC3933074 DOI: 10.1136/annrheumdis-2013-204573] [Citation(s) in RCA: 1433] [Impact Index Per Article: 143.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2013] [Revised: 10/05/2013] [Accepted: 10/11/2013] [Indexed: 02/07/2023]
Abstract
In this article, the 2010 European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs and bDMARDs, respectively) have been updated. The 2013 update has been developed by an international task force, which based its decisions mostly on evidence from three systematic literature reviews (one each on sDMARDs, including glucocorticoids, bDMARDs and safety aspects of DMARD therapy); treatment strategies were also covered by the searches. The evidence presented was discussed and summarised by the experts in the course of a consensus finding and voting process. Levels of evidence and grades of recommendations were derived and levels of agreement (strengths of recommendations) were determined. Fourteen recommendations were developed (instead of 15 in 2010). Some of the 2010 recommendations were deleted, and others were amended or split. The recommendations cover general aspects, such as attainment of remission or low disease activity using a treat-to-target approach, and the need for shared decision-making between rheumatologists and patients. The more specific items relate to starting DMARD therapy using a conventional sDMARD (csDMARD) strategy in combination with glucocorticoids, followed by the addition of a bDMARD or another csDMARD strategy (after stratification by presence or absence of adverse risk factors) if the treatment target is not reached within 6 months (or improvement not seen at 3 months). Tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, biosimilars), abatacept, tocilizumab and, under certain circumstances, rituximab are essentially considered to have similar efficacy and safety. If the first bDMARD strategy fails, any other bDMARD may be used. The recommendations also address tofacitinib as a targeted sDMARD (tsDMARD), which is recommended, where licensed, after use of at least one bDMARD. Biosimilars are also addressed. These recommendations are intended to inform rheumatologists, patients, national rheumatology societies and other stakeholders about EULAR's most recent consensus on the management of RA with sDMARDs, glucocorticoids and bDMARDs. They are based on evidence and expert opinion and intended to improve outcome in patients with RA.
Collapse
|
62
|
Burmester G, Charles-Schoemann C, Isaacs J, Hendrikx T, Kwok K, Zwillich SH, Riese R. THU0238 Tofacitinib, an Oral Janus Kinase Inhibitor: Safety Comparison in Patients with Rheumatoid Arthritis and an Inadequate Response to Nonbiologic or Biologic Disease-Modifying Anti-Rheumatic Drugs. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-eular.766] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
63
|
Burmester G, Müller-Ladner U, Nüsslein H, von Hinuber U, Edelmann E, Detert J, Höhle M, Richter C, Klopsch T, Kumke T, Fricke D. AB0467 Rapid achievement of remission with certolizumab pegol was maintained for one year: interim results from fast, a german non-interventional study in rheumatoid arthritis real life patients. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2012-eular.467] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
64
|
Burmester G, Rigby W, van Vollenhoven R, Kay J, Rubbert-Roth A, Kelman A, Dimonaco S, Mitchell N. OP0041 Tocilizumab (TCZ) in Combination and Monotherapy Versus Methotrexate (MTX) in MTX-Naive Patients (PTS) with Early Rheumatoid Arthritis (RA): Clinical and Radiographic Outcomes from a Randomised, Placebo-Controlled Trial. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-eular.246] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
65
|
Burmester G, Emery P, Signorovitch J, Williams D, Valdes J, Bao Y, Mulani P. FRI0145 The effect of adalimumab on risk of major adverse cardiovascular events in rheumatoid arthritis: A meta-analysis of randomized trials:. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.2602] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
66
|
Baraliakos X, Heldmann F, Callhoff J, Listing J, Appelboom T, Brandt J, van den Bosch F, Breban M, Burmester G, Dougados M, Emery P, Pappas D, Gaston H, Sieper J, de Vlam K, Braun J. OP0172 Inflammation and fatty degeneration are of similar importance for new bone formation in patients with ankylosing spondylitis treated with infliximab or other anti-TNF agents over 5 years. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.1855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
67
|
Burmester G, Takeuchi T, Barbarash O, Ranganna G, Close D, Godwood A, Saurigny D. FRI0232 Consistent efficacy and safety outcomes between european and japanese subjects with rheumatoid arthritis following treatment with mavrilimumab in the phase 2 earth study. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
68
|
Burmester G, Kivitz A, Kupper H, Arulmani U, Florentinus S, Goss S, Rathmann S, Fleischmann R. OP0067 Efficacy, Pharmacokinetics, and Safety of Different Doses of Methotrexate in Combination with Adalimumab: Results from the Concerto Trial. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.272] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
69
|
Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sörensen H, Schmidt R, Sieper J, Braun J. THU0286 Clinical efficacy and safety of infliximab – first results after a decade of continuous treatment in ankylosing spondylitis:. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.2251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
70
|
Baraliakos X, Heldmann F, Listing J, Schett G, Appelboom T, Brandt J, van den Bosch F, Breban M, Burmester G, Dougados M, Emery P, Gaston H, Gruenke M, van der Horst-Bruinsma I, Landewé R, Leirisalo-Repo M, Sieper J, de Vlam K, Braun J. THU0262 Sclerostin does not predict radiographic progression in patients on anti-tnf therapy – new results from the european ankylosing spondylitis (AS) infliximab cohort (EASIC). Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.2227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
71
|
Burmester G, Matucci-Cerinic M, Navarro-Blasco F, Oezer U, Kary S, Unnebrink K, Kupper H. FRI0159 Long-term effectiveness and safety of adalimumab in patients with moderate versus severe rheumatoid arthritis:. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.2616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
72
|
Burmester G, Kivitz AJ, van Vollenhoven RF, Florentinus S, Karunaratne PM, Kupper H, Dougados M, Fleischmann RM. THU0239 Methotrexate Dose has Minimal Effects on Methotrexate-Related Toxicity in Patients with Early Rheumatoid Arthritis Treated in Combination with Adalimumab – Results of Concerto Trial. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
73
|
Burmester G, Weinblatt M, McInnes I, Barbarash O, Esfandieri E, Sleeman M, Godwood A, Magrini F. THU0096 Mavrilimumab in rheumatoid arthritis: Results of a phase 2 double-blind, placebo controlled study. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.2061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
74
|
McInnes IB, Combe B, Burmester G. Understanding the patient perspective - results of the Rheumatoid Arthritis: Insights, Strategies & Expectations (RAISE) patient needs survey. Clin Exp Rheumatol 2013; 31:350-357. [PMID: 23406685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2012] [Accepted: 12/03/2012] [Indexed: 06/01/2023]
Abstract
OBJECTIVES To gain insight into the management and treatment of rheumatoid arthritis (RA) from the perspective of patients with moderate to severe disease. METHODS We recruited patients with moderate-to-severe, active RA who were either biologic naïve or biologic experienced (i.e. receiving biologic therapy) and then surveyed their perceptions of their disease and its management through a questionnaire. The survey was administered by computer-assisted telephone interview of patients in 9 countries (n=586) and covered diagnosis, treatment, physician interaction, and lifestyle with RA. Mean age at onset of RA symptoms was 41 years, with an average time to diagnosis of 3 years. RESULTS Most physician-patient communication centered on symptoms and treatment rather than the impact of RA on quality of life (QoL). Biologic users had significantly more 'good' days per month than biologic-naïve patients (71% vs. 61%). Of all patients, 22% reported high levels of pain on the day of the interview. A majority of patients considered their lives to be controlled by RA, despite the fact that they were receiving the current standard of care. Although potentially eligible for biologic therapy, as defined by a broad set of criteria for this investigation, 62% of biologic-naïve patients were not aware of biologic therapies. CONCLUSIONS The Rheumatoid Arthritis: Insights, Strategies & Expectations (RAISE) survey describes how patients with moderate to severe RA view their disease and which issues are critically important to them. Despite substantial impact on QoL and emotional health, a minority of patients discuss these issues with their physician. Also, despite improvements afforded by biologic therapy, continuing symptoms and pain occur in a proportion of RA patients.
Collapse
|
75
|
Sörensen T, Schulte-Wrede U, Pade S, Hirseland H, Burmester G, Radbruch A, Grützkau A, Häupl T. A10.4 Automated and Standardised Analysis for High Dimensional Cytometric Data Provides New Options for Complex Cell-Associated Biomarker Screening. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-203224.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|